ClinicalTrials.gg
CompletedNCT06732154Updated Apr 3, 2026

A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects

A Phase 1 interventional study of HRS-5632 and Placebo in Dyslipidemia, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies in Dyslipidemias with a site in China — 21 open to participants now, 31 under way, 10 of them phase 3. Dyslipidemias · China.

Enrollment
48th of 56
50 · median 213
Started
2024
with 6 others
Phase 1
6 of 73
1 open now
Registered
55th of 73
by date

Among the 73 studies in Dyslipidemias with a site in China, this one is the 48th largest by enrollment of the 56 interventional ones that give a count, is one of 7 that started in 2024, is one of 6 in phase 1, and was the 55th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

21 of the 73 studies in Dyslipidemias with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Dyslipidemias with a site in China, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of HRS-5632 Following a Single Subcutaneous Injection in Healthy Subjects

03

Conditions studied

  • Dyslipidemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understand the specific procedures of the trial, voluntarily participate in this trial, and sign an form;
  2. Age on the day of signing the informed consent form must be ≥18 and ≤55 years old (inclusive of boundary values);
  3. Male subjects must weigh ≥50 kg and female subjects must weigh ≥45 kg, with a (BMI) within the range of 19 to 30 kg/m² (inclusive of boundary values);
  4. Female subjects with must agree to use effective and avoid donating eggs from the time of signing the informed consent form until the end of the trial. Serum pregnancy tests within 7 days before the first dosing and during the trial must be negative, and they must not be breastfeeding; Male subjects with partners who have childbearing potential must agree to use effective contraception and avoid donating sperm from the time of signing the informed consent form until 6 months after the last administration of the trial medication;
  5. Vital signs, physical examinations, and laboratory tests (complete blood count, urinalysis, blood biochemistry, coagulation function, thyroid function, sex hormones), 12-lead , chest X-ray, and abdominal ultrasound must be normal or have abnormalities without clinical significance.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with any diseases or medical history in the circulatory, endocrine, nervous, digestive, respiratory, hematological, immunological, psychiatric, and metabolic systems, or any other diseases or histories that could interfere with the trial results or any significant laboratory abnormalities judged by the investigator to be clinically meaningful;
  2. History of malignant tumors;
  3. Use of any prescription, over-the-counter, or traditional Chinese medicine within 14 days prior to the study drug administration, or within 7 half-lives of the drug at the time of screening;
  4. Participation in any clinical trial of drugs or medical devices within the last 3 months, or still within 7 half-lives of the drug at the time of screening (the longer standard shall prevail if both are met);
  5. Subjects who plan to take lipid-lowering or lipid-affecting drugs not part of this study during the trial;
  6. Elevated high-sensitivity C-reactive protein >1.5 times the , or /international normalized ratio (PT/INR), activated partial thromboplastin time (APTT) >1.25 times the upper limit of normal during the screening period;
  7. Positive results in infectious disease screening (including surface antigen (HBsAg), virus antibody, antibody, syphilis spirochete antibody);
  8. Abnormal 12-lead with clinical significance, or electrocardiogram (QTcF) > 450 ms in males, > 470 ms in females;
  9. Blood donation or blood loss of ≥ 200 mL within the last month before dosing, or ≥ 400 mL within the last 3 months before dosing, or receipt of blood transfusion within the last 8 weeks;
  10. History of severe infection, severe trauma, or major surgery within the last 3 months before dosing; planning to undergo surgery during the trial and within two weeks after trial completion;
  11. Suspected history of allergy to the study drug or any component of the study drug, allergic constitution, or history of severe drug allergies;
  12. History of difficulty with blood draws or intolerance to venipuncture, such as fainting at the sight of needles or blood;
  13. (eGFR) below 60 mL/min/1.73 m² (estimated using the CKD-EPI equation);
  14. Average daily smoking of ≥ 5 cigarettes in the three months before dosing; average daily alcohol intake exceeding 15 g in the month before dosing (5 g of alcohol is equivalent to 150 mL of beer, 50 mL of wine, about 17 mL of low-proof spirits, or 10 mL of high-proof spirits);
  15. Positive drug screen at the screening visit or positive alcohol breath test;
  16. For subjects participating in QT/QTc studies: (1) Heart rate > 100 bpm, congenital QT interval prolongation syndrome, or family history of congenital QT interval prolongation, with implanted pacemakers, automatic implantable cardioverter-defibrillators; (2) Use of antiarrhythmic drugs, cardiac drugs, beta-blockers, calcium channel blockers, quinolones, and other drugs that prolong QT/QTc interval or cause risk of torsades de pointes (TdP) within 4 weeks before the first use of the trial drug;
  17. Any other conditions deemed by the investigator to make the subject unsuitable for participation in this trial.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    HRS-5632

    Drug: HRS-5632

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugHRS-5632

    HRS-5632 Injection

  • DrugPlacebo

    Sodium chloride injection

06

What researchers measure

Primary outcomes

  1. The percentage of all reported adverse events, serious adverse events and treatment-related adverse events, serious adverse events.

    Time frame: from the single dose administration (Day 1) to Day 337

Secondary outcomes

  1. Area under the concentration time curve (AUC) of HRS-5632

    Time frame: Following a single subcutaneous injection(Day1)to Day4,

  2. Maximum observed drug concentration (Cmax) of HRS-5632

    Time frame: Following a single subcutaneous injection(Day1)to Day4,

07

Study locations

1 site
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin Municipality 300052, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Mar 2026, 15 months.

Of 77 industry-sponsored phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 15 months is above that.

Counting every sponsor, half of 83 studies reached it within 2 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2024
First posted
Dec 13, 2024
StartActual
Dec 2, 2024
Primary completionActual
Mar 2, 2026
CompletionActual
Mar 2, 2026
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06732154
Responsible party
Sponsor
First posted
Dec 13, 2024
Start date
Dec 2, 2024
Primary completion
Mar 2, 2026
Completion
Mar 2, 2026
Last update
Apr 3, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion